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Background
A growing number of cancer patients are at risk from
chronic anthracycline cardiotoxicity (cAC) as a result of
improving cancer prognosis. Susceptibility is cumulative
dose-related, but also idiosyncratic. At present there is
no ideal test to identify those at risk: endomyocardial
biopsy is inappropriate for routine monitoring; while
serial measurement of LV ejection fraction (LVEF) only
identifies cardiotoxicity after significant damage has
been incurred. We hypothesised that risk of cAC could
be determined from a combination of baseline factors
and assessment of the response to the 1st anthracycline
dose. Here we report the associations between cAC and
myocardial insult after cycle 1: assessed by CMR and
high-sensitivity troponin T (hsTnT).
Methods
Women due to receive anthracycline-based chemotherapy
for early breast cancer were recruited to the BETTER-
CARE study. Those with known cardiovascular disease
were excluded. CMR was performed before chemotherapy
and at follow-up (>1 year after the final anthracycline
cycle, and >3 months after Trastuzumab). A subgroup was
studied at baseline and on day-3 after the 1st cycle of
anthracycline with CMR (early gadolinium relative
enhancement, EGRE) and measurement of hsTnT (Roche
Diagnostics). A 2nd subgroup had hsTnT measured after
the final anthracycline cycle (before radiotherapy or trastu-
zumab). LVEF was measured by a single operator (PK) and
EGRE by a 2nd, independent operator (GS). Chronic AC
(cAC) was defined as a fall in absolute LVEF≥5% at
follow-up.
Results
55/60 subjects assessed on day-3 completed follow-up
(median 19 months); 51/55 had paired EGRE and 49/55
hsTnT data. 20% were in the cAC group (N=11). 58
subjects had hsTnT measurements after completing
anthracycline treatment (median 21 days). No patients
developed a rise in hsTnT after cycle 1. However, fol-
lowing the final cycle (median 4), 78% were hsTnT posi-
tive (≥0.004 μg/l). Post-treatment hsTnT was a poor
discriminator of cAC (area under ROC curve of 0.51,
p=0.95). The EGRE response was heterogeneous: median
increase 11.6%, mean 23.8% (p<0.001). EGRE increased
significantly more in those in the cAC group (p=0.02);
area under ROC curve of 0.75 (p=0.01).
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Conclusions
This study shows that myocardial injury (elevated hsTnT)
occurs in the majority of women treated with low-dose
anthracyclines. However, hsTnT cannot discriminate
between those who develop contractile dysfunction and
those who do not. Myocardial inflammation can be
detected after the 1st dose of anthracycline using CMR-
EGRE, before hsTnT rises. Furthermore, the magnitude
of EGRE response is greater in those who later develop
contractile dysfunction due to cAC. Development of this,
or related techniques, may lead to a superior means of
monitoring the cardiotoxic effects of chemotherapy, both
in clinical practice and interventional trials.
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